Lyell Immunopharma to acquire ImmPACT for $87m.

Lyell Immunopharma, a fully integrated company developing next-generation T-cell reprogramming technologies, agreed to acquire ImmPACT, a privately-owned clinical-stage biotechnology company, for $87m. “Lyell’s vision is to bring meaningful and durable clinical benefit to patients suffering from cancer with our next-generation cell therapies,” Lynn Seely, Lyell President and CEO.